Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Silence Therapeutics plc
  6. News
  7. Summary
    SLN   GB00B9GTXM62

SILENCE THERAPEUTICS PLC

(SLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Silence Therapeutics : Hansoh Pharma Agree Therapeutics Development Project

10/15/2021 | 05:19am EST


ę MT Newswires 2021
All news about SILENCE THERAPEUTICS PLC
12/01Silence Therapeutics Welcomes Deep Track Capital as New Shareholder
GL
11/30Silence Therapeutics Begins Exclusive Nasdaq Trading
GL
11/26Silence Therapeutics Says Delisting on UK's AIM Market to Be Effective Nov. 30; To Reta..
MT
11/26SILENCE THERAPEUTICS PLC : Update on AIM Delisting - Form 6-K
PU
11/26Silence Therapeutics to Delist From London's AIM on Nov. 30
MT
11/18SILENCE THERAPEUTICS : Corporate Presentation
PU
11/16SILENCE THERAPEUTICS : Condensed consolidated income statement (unaudited) - Form 6-K
PU
11/16Silence Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months..
CI
11/11Silence Therapeutics to Present at Jefferies London Healthcare Conference
GL
11/08Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder
AQ
More news
Analyst Recommendations on SILENCE THERAPEUTICS PLC
More recommendations
Financials
Sales 2021 13,1 M 17,4 M 17,4 M
Net income 2021 -44,9 M -59,6 M -59,6 M
Net cash 2021 76,7 M 102 M 102 M
P/E ratio 2021 -
Yield 2021 -
Capitalization 505 M 671 M 670 M
EV / Sales 2021 32,7x
EV / Sales 2022 19,2x
Nbr of Employees 65
Free-Float 43,3%
Chart SILENCE THERAPEUTICS PLC
Duration : Period :
Silence Therapeutics plc Technical Analysis Chart | SLN | GB00B9GTXM62 | MarketScreener
Technical analysis trends SILENCE THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Managers and Directors
Mark A. Rothera President, CEO & Executive Director
Craig A. Tooman Chief Financial Officer
Iain Gladstone Ross Non-Executive Chairman
Giles Campion Executive Director & Chief Medical Officer
Alistair William Gray Senior Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SILENCE THERAPEUTICS PLC4.09%671
MODERNA, INC.153.98%107 578
LONZA GROUP AG25.98%56 683
IQVIA HOLDINGS INC.46.84%50 262
SEAGEN INC.-16.63%26 699
CELLTRION, INC.-43.31%23 888